We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clears Ranbaxy’s U.S. Subsidiary of Manufacturing Practice Violations
FDA Clears Ranbaxy’s U.S. Subsidiary of Manufacturing Practice Violations
October 23, 2013
Ranbaxy enjoyed some good news this month when its U.S. subsidiary resolved FDA current good manufacturing practice (cGMP) violations resulting from a 2012 inspection.